All In Biotech

Drug Trial Radar · NCT04542824

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A Phase 1/2, Open-Label, Dose-Escalation Trial With Expansion Cohorts

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

78

Actual

Start

Aug 20, 2020

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
AbbVie
First posted
Sep 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab (EPKINLY™) in Japanese participants with relapsed, progressive or refractory B-cell lymphomas and Japanese participants with B-cell lymphomas that have achieved partial response (PR) or complete response (CR) following prior standard of care (SOC). The trial consists of two parts: Part 1, dose escalation (phase 1), and Part 2, expansion (phase 2). The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase-2 dose (RP2D), as well as to establish the safety profile of epcoritamab in Japanese participants with relapsed, progressive or refractory B-cell lymphoma and Japanese participants with B-cell lymphomas that have achieved PR or CR. In the expansion part, additional participants will be treated with epcoritamab, at the RP2D and the purpose is to further explore and determine the safety and efficacy of epcoritamab. Part 2 of the trial will be initiated once the RP2D has been determined in Part 1. In Part 2, epcoritamab is investigated as a monotherapy and in combination with other SOC agents.

Conditions

  • Diffuse Large B Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Primary Mediastinal Large B Cell Lymphoma
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Small Lymphocytic Lymphoma

Interventions

  • Epcoritamab (monotherapy)Biological

    Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)

  • EpcoritamabBiological

    Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.

  • Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisoneDrug

    21-day cycles

  • Gemcitabine and oxaliplatinDrug

    28-day cycles

  • Epcoritamab (maintenance)Biological

    28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13

  • Rituximab and lenalidomideDrug

    28-day cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years
  2. Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: DLTs are assessed during the first cycle (28 days) in each cohort
  3. Part 2, Arm 1: Objective Response Rate (ORR)Time frame: Up to 1.5 years
  4. Part 2, Arms 2-4: Number of Participants with DLTsTime frame: DLTs are assessed during the first cycle (28 days) in arms 2-4
  5. Part 2, Arms 2-5: Number of Participants with TEAEsTime frame: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Aichi Cancer Center Hospital

    Aichi, Japan

  • NHO Nagoya Medical Center

    Aichi, Japan

  • National Cancer Center Hospital East

    Chiba, Japan

  • Matsuyama Red Cross Hospital

    Ehime, Japan

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Japan

  • Fukushima Medical University Hospital

    Fukushima, Japan

  • Kagoshima University Hospital

    Kagoshima, Japan

  • Kyoto University Hospital

    Kyoto, Japan

  • Kindai University Hospital

    Osaka, Japan

  • Osaka University Hospital

    Osaka, Japan

  • Cancer Institute Hospital of JFCR

    Tokyo, Japan

  • National Cancer Center Hospital

    Tokyo, Japan

  • Tokyo Medical University Hospital

    Tokyo, Japan

  • Yamagata University Hospital

    Yamagata, Japan

  • Tohoku University Hoaspital

    Sendai, Miyagi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.